Lineage Cell Therapeutics, Inc. (LCTX) stock
LCTXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/3048% above fair value
$0.91−0.08 (-7.64%)
Close on Nov 13, 2026Market cap $231.31MP/E –Yield –
Lineage Cell Therapeutics cash
Cash and short-term investments held at the end of each period.
Lineage Cell Therapeutics's cash was $45.18M at Sep 30, 2026. For fiscal 2025 it was $55.78M, up 15.3% from the year before. Over ten years it grew 2.8% a year on average. The highest annual figure on record is $58.46M in fiscal 2022.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.78M | +15.3% |
| FY2024 | Dec 31, 2024 | $48.37M | +34.2% |
| FY2023 | Dec 31, 2023 | $36.04M | -38.3% |
| FY2022 | Dec 31, 2022 | $58.46M | +0.1% |
| FY2021 | Dec 31, 2021 | $58.40M | +40.4% |
| FY2020 | Dec 31, 2020 | $41.60M | +35.5% |
| FY2019 | Dec 31, 2019 | $30.70M | 0.0% |
| FY2018 | Dec 31, 2018 | $30.70M | -19.6% |
| FY2017 | Dec 31, 2017 | $38.20M | +205.6% |
| FY2016 | Dec 31, 2016 | $12.50M | -70.4% |
| FY2015 | Dec 31, 2015 | $42.23M | +43.2% |
| FY2014 | Dec 31, 2014 | $29.49M | +436.5% |
| FY2013 | Dec 31, 2013 | $5.50M | +26.3% |
| FY2012 | Dec 31, 2012 | $4.35M | -80.4% |
| FY2011 | Dec 31, 2011 | $22.21M | -33.3% |
| FY2010 | Dec 31, 2010 | $33.32M | +173.4% |
| FY2009 | Dec 31, 2009 | $12.19M | +99167.7% |
| FY2008 | Dec 31, 2008 | $12.28K | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $45.18M | +11.6% |
| Q2 FY2026 | Jun 30, 2026 | $50.83M | +20.2% |
| Q1 FY2026 | Mar 31, 2026 | $53.38M | +11.4% |
| Q4 FY2025 | Dec 31, 2025 | $55.78M | +15.3% |
| Q3 FY2025 | Sep 30, 2025 | $40.49M | +23.8% |
| Q2 FY2025 | Jun 30, 2025 | $42.29M | +9.9% |
| Q1 FY2025 | Mar 31, 2025 | $47.91M | +9.8% |
| Q4 FY2024 | Dec 31, 2024 | $48.37M | +34.2% |
| Q3 FY2024 | Sep 30, 2024 | $32.71M | -20.9% |
| Q2 FY2024 | Jun 30, 2024 | $38.50M | -16.2% |
| Q1 FY2024 | Mar 31, 2024 | $43.62M | -6.8% |
| Q4 FY2023 | Dec 31, 2023 | $36.04M | -38.3% |
| Q3 FY2023 | Sep 30, 2023 | $41.33M | -37.7% |
| Q2 FY2023 | Jun 30, 2023 | $45.93M | -36.2% |
| Q1 FY2023 | Mar 31, 2023 | $46.81M | -41.4% |
| Q4 FY2022 | Dec 31, 2022 | $58.46M | +0.1% |
| Q3 FY2022 | Sep 30, 2022 | $66.36M | +1.9% |
| Q2 FY2022 | Jun 30, 2022 | $72.03M | +4.8% |
| Q1 FY2022 | Mar 31, 2022 | $79.94M | +28.1% |
| Q4 FY2021 | Dec 31, 2021 | $58.40M | +40.4% |
| Q3 FY2021 | Sep 30, 2021 | $65.10M | +71.3% |
| Q2 FY2021 | Jun 30, 2021 | $68.70M | +238.4% |
| Q1 FY2021 | Mar 31, 2021 | $62.40M | +141.9% |
| Q4 FY2020 | Dec 31, 2020 | $41.60M | +35.5% |
| Q3 FY2020 | Sep 30, 2020 | $38.00M | +6.4% |
| Q2 FY2020 | Jun 30, 2020 | $20.30M | +21.6% |
| Q1 FY2020 | Mar 31, 2020 | $25.80M | -4.8% |
| Q4 FY2019 | Dec 31, 2019 | $30.70M | 0.0% |
| Q3 FY2019 | Sep 30, 2019 | $35.70M | +66.5% |
| Q2 FY2019 | Jun 30, 2019 | $16.70M | -42.8% |
| Q1 FY2019 | Mar 31, 2019 | $27.10M | -13.7% |
| Q4 FY2018 | Dec 31, 2018 | $30.70M | -19.6% |
| Q3 FY2018 | Sep 30, 2018 | $21.44M | +28.7% |
| Q2 FY2018 | Jun 30, 2018 | $29.20M | +100.7% |
| Q1 FY2018 | Mar 31, 2018 | $31.40M | +27.3% |
| Q4 FY2017 | Dec 31, 2017 | $38.20M | +205.6% |
| Q3 FY2017 | Sep 30, 2017 | $16.66M | – |
| Q2 FY2017 | Jun 30, 2017 | $14.55M | – |
| Q1 FY2017 | Mar 31, 2017 | $24.66M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.50M | – |
See a number that looks wrong?